Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis

2 May 2014

Abstract excerpt

Systemic Mastocytosis (SM) is a clonal disease characterized by abnormal accumulation of mast cells in multiple organs. Clinical presentations of the disease vary widely from indolent to aggressive forms, and to the exceedingly rare mast cell leukemia. Current treatment of aggressive SM and mast cell leukemia is unsatisfactory. An imatinib-resistant activating mutation of the receptor tyrosine kinase KIT (KIT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Mast cells and histamine

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24788138
DOI: 10.1371/journal.pone.0096209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of MastocytosisPMID 24788138Read ↗

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.Semantic proximity Read ↗

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.Semantic proximity Read ↗

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.Semantic proximity Read ↗

SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.Semantic proximity Read ↗

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Semantic proximity Read ↗

Molecular defects in mastocytosis: KIT and beyond KIT.Semantic proximity Read ↗

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.Semantic proximity Read ↗

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.Semantic proximity Read ↗

New Insights into the Pathogenesis of Systemic Mastocytosis.Semantic proximity Read ↗

Molecular basis of mast cell disease.Semantic proximity Read ↗

Recent advances in the understanding and therapeutic management of mastocytosisSemantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.